MDL Judge Denies Interlocutory Appeal Of AndroGel Failure-To- Warn Preemption Issue
CHICAGO — The Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on Sept. 18 denied a motion by defendants AbbVie Inc. and Abbott Laboratories to certify for interlocutory appeal...To view the full article, register now.
Already a subscriber? Click here to view full article